First Annual Wound Care 2022 in united states | 3M

 The global active wound care market size was valued at USD 1,361.7 Million in 2017 and projected to reach USD 2,039.9 Million by 2025, exhibiting a CAGR of 5.2% in the forecast period.

Transforming wound care through science 

Your goal is to protect and support your patient along their surgical journey, hospital stay or clinic visit. We are here to help address your challenges with leading innovations in negative pressure wound therapy (NPWT), surgical incision management, infection prevention, advanced wound care and skin integrity to help meet the needs of the people you care for every day.

No matter your patients’ needs, we are with you and your team every step of the way. We provide you with innovative products that are rooted in clinical evidence, helping you accelerate patient healing and drive more effective outcomes. 

Get a Sample Copy of the Report at – https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100172

This multidisciplinary conference will focus on emerging care modatlities in the recognition, assessment and management of wounds for patients transitioning from acute to the outpatient settings. The most up to date and best practice information on acute and chronic wound care will be addressed. Participants will examine and have the opportunity to learn and discuss key factors essential to wound healing including Nutrition, Vascular assessment and treatment, Lymphedema and the role infectious diseases can have in healing. 

Credit will be awarded based on participant selection at time of registration. Contact hours will be awarded to all participants. Before selecting credits, please review our general Credit Glossary, but note that not all programs offer all credits.

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to the publisher's digital archives and Research Platform
  • Complimentary updates for one year

Key players covered in the global Active Wound Care Market research report:

  • MiMedx
  • Tissue Regenix
  • Smith & Nephew
  • Organogenesis Inc.
  • Acell Inc.
  • Integra Life Sciences
  • Solsys Medical
  • Osiris Therapeutics, Inc.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Comments

Post a Comment

Popular posts from this blog

US Market Trends For Computer-Assisted & Robotics-Assisted Surgery

  In the medical industry, adoption of new cutting-edge technology is slow compared to other industries, such as the automotive industry. 1  Computer-assisted and robotic-assisted surgery (CAS and RAS, respectively) have been around for decades, yet a small percentage of procedures performed take advantage of the innovative solutions available on the market today. In coming years, the number of procedures using robotics and surgical navigation is predicted to increase at a double-digit rate year over year to reach over 6 million procedures by 2028. 2  This rise in CAS and RAS can be attributed to the predicted increase in the utilization of navigation systems and robotic devices as more companies launch new or next-generation systems for assisted surgery. Reasons For Slow CAS And RAS Adoption Some argue that using CAS and RAS is not worth the time and monetary investment, as using this technology often increases procedure planning time and reduces the number of procedures...
Read more

Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer

  Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer   Health Canada approved nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer prior to surgery. Nivolumab (Opdivo) plus platinum-doublet chemotherapy has been approved by Health Canada for the treatment of certain patients with resectable non–small cell lung cancer, according to Bristol Meyers Squibb. The approval was based on results from the phase 3 CheckMate 816 trial (NCT02998528), in which neoadjuvant nivolumab plus chemotherapy resulted in a 37% reduction in risk of disease progression, recurrence, or death vs chemotherapy alone among patients with resectable NSCLC (HR, 0.63; 97.38%, 0.43-0.91;  P  = .005). The median event-free survival (EFS) with nivolumab/chemotherapy was 31.6 months vs 20.8 months with chemotherapy alone. Improvement in the rate of pathologica...
Read more

USA – Overview of Prothrombin Complex Concentrate Industry and Healthcare Statistics in 2022

Image
The global   Prothrombin Complex Concentrate (PCC) market size  was valued at USD 695.3 million in 2019 and is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6 % during the forecast period Abstract Left ventricular assist devices (LVADs) require careful therapeutic anticoagulation with warfarin to prevent pump thrombosis. However, the best method to reverse warfarin for elective LVAD conversion surgery with massive bleeding remains unclear. We report the case of a 39-year-old Japanese man who was administered a four-factor prothrombin complex concentrate (4F-PCC) as warfarin reversal when he underwent conversion surgery from paracorporeal LVAD to implantable LVAD. 4F-PCC with co-administration of vitamin K reduced the international normalized ratio and R time in TEG6s (Haemonetics Corporation, USA) immediately. The effect was prolonged, and good hemostasis was achieved. 4F-PCC with vitamin K provided good hemostasis in our patient; therefore, 4F-PCC co...
Read more